AstraZeneca UK LTD 4
4 · Viela Bio, Inc. · Filed Oct 9, 2019
Insider Transaction Report
Form 4
ASTRAZENECA PLC
10% Owner
Transactions
- Conversion
Common Stock
2019-10-07+14,225,324→ 14,225,334 total(indirect: See footnote) - Purchase
Common Stock
2019-10-07$19.00/sh+425,000$8,075,000→ 14,650,334 total(indirect: See footnote) - Conversion
Series A-1 Preferred Stock
2019-10-07−14,225,324→ 0 total(indirect: See footnote)→ Common Stock (14,225,324 underlying)
Footnotes (5)
- [F1]The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis.
- [F2]All of these securities are owned by AstraZeneca UK Limited, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the shares held by AstraZeneca UK Limited, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any.
- [F3]Reflects shares purchased in the Issuer's initial public offering.
- [F4]The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.
- [F5]Not applicable.